Literature DB >> 17868757

Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study: practical outcomes and implications for depression treatment in primary care.

Robert A Cain1.   

Abstract

The Sequenced Treatment Alternatives to Relieve Depression (STAR( *)D) study addressed many clinically relevant issues on treatment of depressed outpatients. The study used an equipoise-stratified randomization scheme that enhanced the real-world expediency of treatment options studied. Because patients who had significant comorbid medical and psychiatric problems were included, and care was provided in the outpatient primary care setting as well as in outpatient psychiatric centers, findings are relevant to primary care physicians. The use of measurement-based treatment protocols promotes objectivity in a realm of often subjective clinical decision making. Although STAR( *)D was unable to provide specific treatment comparisons for patients at all study levels, it succeeded in defining the prevalence of treatment-resistant depression and is a model for further practical clinical outcomes studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868757     DOI: 10.1016/j.pop.2007.05.006

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  18 in total

Review 1.  [Treatment pathways in the care of patients with schizophrenia and depression].

Authors:  H J Salize; E Voß; A Werner; P Falkai; I Hauth
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  Randomized Clinical Trial of Real-Time fMRI Amygdala Neurofeedback for Major Depressive Disorder: Effects on Symptoms and Autobiographical Memory Recall.

Authors:  Kymberly D Young; Greg J Siegle; Vadim Zotev; Raquel Phillips; Masaya Misaki; Han Yuan; Wayne C Drevets; Jerzy Bodurka
Journal:  Am J Psychiatry       Date:  2017-04-14       Impact factor: 18.112

3.  PsyScan e-tool to support diagnosis and management of psychological problems in general practice: a randomised controlled trial.

Authors:  Luc G Gidding; Mark Spigt; Bjorn Winkens; Odette Herijgers; Geert-Jan Dinant
Journal:  Br J Gen Pract       Date:  2017-12-18       Impact factor: 5.386

Review 4.  Amygdala real-time functional magnetic resonance imaging neurofeedback for major depressive disorder: A review.

Authors:  Kymberly D Young; Vadim Zotev; Raquel Phillips; Masaya Misaki; Wayne C Drevets; Jerzy Bodurka
Journal:  Psychiatry Clin Neurosci       Date:  2018-05-21       Impact factor: 5.188

5.  Resting-state functional connectivity modulation and sustained changes after real-time functional magnetic resonance imaging neurofeedback training in depression.

Authors:  Han Yuan; Kymberly D Young; Raquel Phillips; Vadim Zotev; Masaya Misaki; Jerzy Bodurka
Journal:  Brain Connect       Date:  2014-11

6.  Depression screening using mobile phone usage metadata: a machine learning approach.

Authors:  Rouzbeh Razavi; Amin Gharipour; Mojgan Gharipour
Journal:  J Am Med Inform Assoc       Date:  2020-04-01       Impact factor: 4.497

7.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

8.  Toward personalizing treatment for depression: predicting diagnosis and severity.

Authors:  Sandy H Huang; Paea LePendu; Srinivasan V Iyer; Ming Tai-Seale; David Carrell; Nigam H Shah
Journal:  J Am Med Inform Assoc       Date:  2014-07-02       Impact factor: 4.497

9.  Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care.

Authors:  Antoni Sicras-Mainar; Jorge Maurino; Luis Cordero; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  Ann Gen Psychiatry       Date:  2012-08-03       Impact factor: 3.455

10.  Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder.

Authors:  Kymberly D Young; Vadim Zotev; Raquel Phillips; Masaya Misaki; Han Yuan; Wayne C Drevets; Jerzy Bodurka
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.